Pharmaceutical

EC grants orphan drug designation for Precigen’s PRGN-2012

The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).

Jan 17, 2024 - 18:00
EC grants orphan drug designation for Precigen’s PRGN-2012
The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).
Read the original article

Tags:

Previous Article

FDA approves Vertex’s gene-edited therapy for beta thalassemia

Next Article

Disco Pharmaceuticals Unveils Surfaceome Mapping for Enhanced Cancer Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novartis expands Cosentyx reach for rheumatic diseases with IV version approval

Novartis expands Cosentyx reach for rheumatic diseases ...

Oct 9, 2023

Risk adjusted net present value: What is the current valuation of Merck’s MRNA-4157?

Risk adjusted net present value: What is the current va...

Nov 18, 2023

DEA will delay telemedicine restrictions for buprenorphine, Adderall, and other drugs

DEA will delay telemedicine restrictions for buprenorph...

May 3, 2023